Insulet (NASDAQ:PODD - Get Free Report) was downgraded by stock analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating in a research report issued on Wednesday, Marketbeat Ratings reports. They presently have a $165.00 price objective on the medical instruments supplier's stock, down from their previous price objective of $180.00. Stifel Nicolaus's target price suggests a potential upside of 13.53% from the stock's previous close.
A number of other equities analysts also recently commented on the company. Royal Bank Of Canada boosted their price objective on Insulet from $160.00 to $180.00 and gave the stock an "outperform" rating in a research report on Thursday, November 5th. UBS Group upped their target price on shares of Insulet from $150.00 to $171.00 and gave the stock a "neutral" rating in a research note on Thursday, November 5th. Canaccord Genuity Group reduced their target price on shares of Insulet from $249.00 to $179.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. JPMorgan Chase & Co. lifted their price target on shares of Insulet from $152.00 to $170.00 and gave the stock a "neutral" rating in a research note on Thursday, November 5th. Finally, Jefferies Financial Group reiterated a "buy" rating and set a $200.00 price target on shares of Insulet in a report on Wednesday, November 4th. Eleven analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $185.04.
Read Our Latest Stock Report on Insulet
Insulet Price Performance
PODD opened at $145.34 on Wednesday. The stock's 50-day moving average price is $142.16 and its 200 day moving average price is $172.43. Insulet has a 12-month low of $126.40 and a 12-month high of $354.88. The company has a current ratio of 2.51, a quick ratio of 1.83 and a debt-to-equity ratio of 0.60. The firm has a market cap of $10.08 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 1.11 and a beta of 1.06.
Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, beating analysts' consensus estimates of $1.59 by $0.40. The company had revenue of $842.00 million during the quarter, compared to analysts' expectations of $832.63 million. Insulet had a return on equity of 31.76% and a net margin of 13.44%. Insulet's revenue for the quarter was up 19.2% on a year-over-year basis. During the same period last year, the business posted $1.24 EPS. As a group, sell-side analysts expect that Insulet will post 6.76 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. OneDigital Investment Advisors LLC acquired a new position in Insulet during the second quarter worth about $6,741,000. Headlands Technologies LLC lifted its position in shares of Insulet by 2,041.5% during the 2nd quarter. Headlands Technologies LLC now owns 31,930 shares of the medical instruments supplier's stock valued at $4,861,000 after acquiring an additional 30,439 shares during the period. Amundi lifted its position in shares of Insulet by 13.6% during the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier's stock valued at $77,320,000 after acquiring an additional 60,929 shares during the period. Man Group plc acquired a new stake in shares of Insulet during the 2nd quarter valued at approximately $78,746,000. Finally, Deutsche Bank AG purchased a new stake in shares of Insulet during the 2nd quarter worth approximately $51,153,000.
About Insulet
(
Get Free Report)
Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.